Mayumi Tokunaga
Kagoshima University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mayumi Tokunaga.
Leukemia & Lymphoma | 2017
Mayumi Tokunaga; Hirofumi Uto; Syogo Takeuchi; Nakano N; Kubota A; Yoshifusa Takatsuka; Masao Seto; Akio Ido; Atae Utsunomiya
Abstract To explore pre-transplantation prognostic factors for adult T-cell leukemia-lymphoma (ATL), we retrospectively analyzed allogeneic hematopoietic stem cell transplantation (allo-HSCT) in 70 patients at our institute (63 acute type and seven lymphoma type patients). Forty-five patients died after HSCT and the three-year overall survival (OS) rate was 35.2%. By univariate analysis, the adverse prognostic factors for OS were performance status ≥2, hematopoietic cell transplantation-specific comorbidity index (HCT-CI) score ≥3, European Group for Blood and Marrow Transplantation (EBMT) risk score ≥5, HSCT from an HLA-mismatched donor, serum soluble interleukin-2 receptor (sIL-2R) level ≥10,000 U/mL, lymphocyte count ≥4000/μL, and hemoglobin <9 g/dL at the time of HSCT. EBMT risk score and sIL-2R were identified as significant adverse prognostic factors using multivariate analysis. This analysis clearly demonstrates for the first time that HCT-CI and EBMT risk scores are reliable prognostic factors for ATL patients receiving allo-HSCT.
Leukemia Research | 2009
Kouichi Haraguchi; Nobuhito Ohno; Masahito Tokunaga; Mayumi Tokunaga; Takahiro Itoyama; Minako Gotoh; Masafumi Taniwaki; Hirohito Tubouchi
Most cases of acute promyelocytic leukemia (APL) are characterized by the reciprocal translocation t(15;17); however, several complex variant translocations have also been reported. Here we report complex cytogenetic abnormalities without t(15;17) assayed by the G-banding method in a 62-year-old woman with the typical morphology and clinical features of APL. Based on spectral karyotyping and FISH analyses, we confirm the insertion of a cryptic chromosomal segment containing the PML/RARalpha fusion gene. The patient achieved complete remission after treatment with all-trans retinoic acid (ATRA) alone. Although the mechanism of this cryptic variant insertion is not known, we conclude that the insertion of PML-RARalpha fusion into 4q21 seems not to alter the effectiveness of treatment with ATRA.
Experimental and Therapeutic Medicine | 2012
Kouichi Haraguchi; Hirofumi Uto; Nobuhito Ohnou; Masahito Tokunaga; Mayumi Tokunaga; Atae Utsunomiya; Shuichi Hanada; Hirohito Tsubouchi
Prohepcidin is the prohormone of hepcidin. Anemia is one of the main clinical features in patients with multiple myeloma (MM) and hepcidin may be associated with iron homeostasis in these patients. However, the clinical significance of prohepcidin is not fully understood. In this retrospective study, we measured serum prohepcidin levels using an immunoassay technique to study its clinical significance in 39 MM patients. Serum prohepcidin levels in patients with MM were weakly correlated with alkaline phosphatase (ALP) levels (r=0.32, P=0.048), calculated by Spearman’s rank correlation, but not with other clinical data, including hemoglobin, serum iron or ferritin. In addition, patients with severe renal insufficiency [creatinine clearance (CCr) <50 ml/min] had significantly higher prohepcidin levels compared with patients with mild or no renal insufficiency (CCr ≥50 ml/min, P=0.047). In contrast, low serum prohepcidin levels less than 110 ng/ml were an independent predictor of poor overall survival [hazard ratio (HR), 5.29; 95% confidence interval (CI), 1.65–17.03] in addition to serum creatinine levels of at least 2 mg/dl (HR, 5.32; CI, 1.10–25.64), serum calcium (HR, 3.53; CI, 1.01–12.33) and ECOG performance status grade 4 (HR, 4.15; CI, 1.32–13.09) in the multivariate analysis using Cox proportional hazards model. In the subset of 31 MM patients with CCr ≥50 ml/min, low serum prohepcidin (HR, 5.65; CI, 1.60–19.95) was an indicator of poor prognosis in multivariate analysis. These results indicate that serum prohepcidin levels may be associated with ALP and renal function but not iron homeostasis, in MM patients. In addition, lower serum prohepcidin levels are potential independent indicators of poor overall survival in MM patients regardless of renal function.
Journal of Gastroenterology | 2014
Mayumi Tokunaga; Hirofumi Uto; Kohei Oda; Masahito Tokunaga; Seiichi Mawatari; Kotaro Kumagai; Kouichi Haraguchi; Makoto Oketani; Akio Ido; Nobuhito Ohnou; Atae Utsunomiya; Hirohito Tsubouchi
Cancer Genetics and Cytogenetics | 2007
Satsuki Owatari; Kimiharu Uozumi; Kouichi Haraguchi; Nobuhito Ohno; Masahito Tokunaga; Mayumi Tokunaga; Shinsuke Suzuki; Shuichi Hanada; Naomichi Arima
Clinical and Laboratory Haematology | 2006
Satsuki Owatari; Kimiharu Uozumi; Masahito Tokunaga; Mayumi Tokunaga; Kouichi Haraguchi; Shinsuke Suzuki; Naomichi Arima
Biology of Blood and Marrow Transplantation | 2016
Nobuaki Nakano; Yoshifusa Takatsuka; Ayumu Kubota; Mashahito Tokunaga; Mayumi Tokunaga; Torahiko Makino; Shogo Takeuchi; Atae Utsunomiya
Blood | 2015
Nobuaki Nakano; Yoshifusa Takatsuka; Ayumu Kubota; Masahito Tokunaga; Mayumi Tokunaga; Torahiko Makino; Shogo Takeuchi; Atae Utsunomiya
Biology of Blood and Marrow Transplantation | 2015
Nobuaki Nakano; Takahiro Itoyama; Ayumu Kubota; Mashahito Tokunaga; Mayumi Tokunaga; Torahiko Makino; Shogo Takeuchi; Yoshifusa Takatsuka; Atae Utsunomiya
Blood | 2014
Masahito Tokunaga; Nobuaki Nakano; Ayumu Kubota; Mayumi Tokunaga; Takahiro Itoyama; Torahiko Makino; Shogo Takeuchi; Yoshifusa Takatsuka; Atae Utsunomiya